Veterinary Medicine Research & Development, Pfizer Animal Health, 7000 Portage Road, Kalamazoo, Michigan 49001, USA.
Future Med Chem. 2011 May;3(7):887-96. doi: 10.4155/fmc.11.39.
Despite investment in programs to manage the development of resistance to existing agents, this continues to drive the need for discovery of novel antiparasitic agents for veterinary medicine. Historically, antiparasitic drug discovery was driven by empirical screening, but technological advances have lead to an increased focus on mechanism-based approaches to drug discovery and this is projected to increase as our capabilities advance to improve both the throughput of assays and the quality of data generated. Investment in the development of combination products with novel agents is increasing and, despite regulatory hurdles in some regions, efforts to globally harmonize regulations will aid in delivering safe, efficacious drugs to help in resistance management and integrated parasite control programs.
尽管投入了资金用于管理现有药物的耐药性发展,但这仍然推动了对兽医新型抗寄生虫药物的发现。从历史上看,抗寄生虫药物的发现是通过经验性筛选驱动的,但技术进步导致了对基于机制的药物发现方法的关注增加,并且随着我们的能力提高以提高测定的通量和生成数据的质量,这种关注预计会增加。投资于具有新型制剂的联合产品的开发正在增加,尽管在一些地区存在监管障碍,但全球协调监管的努力将有助于提供安全有效的药物,以帮助管理耐药性和综合寄生虫控制计划。